Olanzapine NDC 59746-308

NDC codes

FDA NDC Directory

Product NDC (as listed)59746-308Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59746-0308Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59746-308-32	59746030832	3 BLISTER PACK in 1 CARTON (59746-308-32) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (59746-308-12)Marketed from Sep 13, 2012

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Olanzapine
Generic name (nonproprietary): olanzapine
Active ingredients: Olanzapine — 15 mg/1
Dosage form: Tablet, Orally disintegrating
Route: Oral
Labeler: Jubilant Cadista Pharmacuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 200221
Marketing start: Sep 13, 2012
Listing expires: Dec 31, 2026
Identifiers: Product ID 59746-308_fddf60eb-156f-4e8c-9bad-3942d714fdceSPL ID fddf60eb-156f-4e8c-9bad-3942d714fdceSPL set ID 028aa88e-fa50-7aa8-cc0b-97c0c9a0357cRxCUI 312076, 314155, 351107, 351108UNII N7U69T4SZRUPC 0359746307325, 0359746306328, 0359746309329, 0359746308322
Pharmacologic class: Atypical Antipsychotic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459746030832 followed by a unit qualifier and the quantity

Package 59746-0308-32. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 27, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Olanzapine orally disintegrating tablets are atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. ( 1.1 ) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 13 to 17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 200221

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 200221
Product	Strength	Form · route	Labeler	Product NDC
Olanzapine	Olanzapine 10 mg/1	Tablet, Orally disintegratingOral	Jubilant Cadista Pharmacuticals Inc.	59746-307
Olanzapine	Olanzapine 5 mg/1	Tablet, Orally disintegratingOral	Jubilant Cadista Pharmacuticals Inc.	59746-306
Olanzapine	Olanzapine 20 mg/1	Tablet, Orally disintegratingOral	Jubilant Cadista Pharmacuticals Inc.	59746-309